The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae. Most meropenem-nonsusceptible metallo-β-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Isolates that carried KPC or OXA-48-like β-lactamases, both alone and in combination with extended-spectrum β-lactamases (ESBLs) and/or AmpC β-lactamases, were 98.7% and 98.5% susceptible to ceftazidime-avibactam, respectively. Meropenem-nonsusceptible, carbapenemase-negative isolates demonstrated 94.7% susceptibility to ceftazidimeavibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-β-lactamases.
CITATION STYLE
De Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016). In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrobial Agents and Chemotherapy, 60(5), 3163–3169. https://doi.org/10.1128/AAC.03042-15
Mendeley helps you to discover research relevant for your work.